Zoetis Inc. (NYSE:ZTS) Shares Purchased by New Age Alpha Advisors LLC

Key Points

• New Age Alpha Advisors LLC has increased its holdings in Zoetis Inc. by 119% during the first quarter, owning a total of 54,393 shares valued at $8,956,000.
• Zoetis recently reported quarterly earnings, beating estimates with an EPS of $1.48 and revenues of $2.22 billion, reflecting a year-over-year revenue increase of 1.4%.
• The company announced a quarterly dividend of $0.50 per share, translating to an annualized dividend yield of 1.3%.

New Age Alpha Advisors LLC lifted its holdings in Zoetis Inc. (NYSE:ZTS - Free Report) by 119.0% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 54,393 shares of the company's stock after purchasing an additional 29,555 shares during the period. New Age Alpha Advisors LLC's holdings in Zoetis were worth $8,956,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Navigoe LLC purchased a new stake in shares of Zoetis in the 4th quarter valued at approximately $30,000. Cornerstone Planning Group LLC raised its stake in Zoetis by 79.3% in the first quarter. Cornerstone Planning Group LLC now owns 199 shares of the company's stock valued at $30,000 after buying an additional 88 shares in the last quarter. Migdal Insurance & Financial Holdings Ltd. raised its stake in Zoetis by 87.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 257 shares of the company's stock valued at $42,000 after buying an additional 120 shares in the last quarter. Sound Income Strategies LLC raised its stake in Zoetis by 141.4% in the first quarter. Sound Income Strategies LLC now owns 280 shares of the company's stock valued at $46,000 after buying an additional 164 shares in the last quarter. Finally, Bfsg LLC raised its stake in Zoetis by 614.6% in the first quarter. Bfsg LLC now owns 293 shares of the company's stock valued at $48,000 after buying an additional 252 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company's stock.

Zoetis Stock Up 3.3%

ZTS stock opened at $152.31 on Tuesday. The company has a fifty day moving average price of $158.29 and a 200 day moving average price of $160.26. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $200.33. The company has a market cap of $67.81 billion, a price-to-earnings ratio of 27.34, a price-to-earnings-growth ratio of 2.44 and a beta of 0.88. The company has a debt-to-equity ratio of 1.12, a current ratio of 1.74 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The firm had revenue of $2.22 billion during the quarter, compared to the consensus estimate of $2.20 billion. Zoetis had a net margin of 27.12% and a return on equity of 55.48%. Zoetis's revenue for the quarter was up 1.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.38 EPS. Sell-side analysts expect that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 1.3%. The ex-dividend date of this dividend is Friday, July 18th. Zoetis's payout ratio is currently 35.91%.

Wall Street Analyst Weigh In

A number of research firms have weighed in on ZTS. UBS Group cut their price target on Zoetis from $189.00 to $170.00 and set a "neutral" rating on the stock in a research note on Wednesday, May 7th. Stifel Nicolaus downgraded shares of Zoetis from a "buy" rating to a "hold" rating and reduced their price objective for the stock from $165.00 to $160.00 in a research report on Wednesday, June 18th. Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an "overweight" rating in a research report on Monday, May 12th. Leerink Partners downgraded shares of Zoetis from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $180.00 to $155.00 in a research report on Thursday, July 17th. Finally, Leerink Partnrs downgraded shares of Zoetis from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 17th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $204.63.

Insider Transactions at Zoetis

In other Zoetis news, EVP Roxanne Lagano sold 652 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $170.00, for a total value of $110,840.00. Following the transaction, the executive vice president directly owned 15,129 shares of the company's stock, valued at approximately $2,571,930. The trade was a 4.13% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.16% of the company's stock.

Zoetis Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.